» » »

Chemo Regimen for Ovarian Cancer Cary NC

Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say. Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients in Cary, according to the new study findings.

Cary N Robertson MD
(919) 681-6788
DUMC 3833
Durham, NC
Specialties
Urology

Data Provided by:
Kevin Paul Khoudary, MD
(919) 467-3203
105 SW Cary Pkwy Ste 300
Cary, NC
Specialties
Urology
Gender
Male
Education
Medical School: Umdnj-Robt W Johnson Med Sch, New Brunswick Nj 08901
Graduation Year: 1991

Data Provided by:
Kevin P Khoudary
(919) 467-3203
105 Sw Cary Pkwy
Cary, NC
Specialty
Urology

Data Provided by:
Barry Russell Lee, MD
(919) 467-3203
105 SW Cary Pkwy Ste 300
Cary, NC
Specialties
Urology
Gender
Male
Education
Medical School: Tulane Univ Sch Of Med, New Orleans La 70112
Graduation Year: 1987
Hospital
Hospital: Carolinas Med Ctr, Charlotte, Nc
Group Practice: Gaston Urological Assoc

Data Provided by:
Henry A Unger
(919) 467-3203
105 Sw Cary Pkwy
Cary, NC
Specialty
Urology

Data Provided by:
Bernard S Lebenson, MD
(919) 467-3203
2212 Upper Valley Ct
Cary, NC
Specialties
Urology
Gender
Male
Education
Medical School: Va Commonwealth Univ, Med Coll Of Va Sch Of Med, Richmond Va 23298
Graduation Year: 1977

Data Provided by:
Benjamin C Lee
(919) 467-3203
105 Sw Cary Pkwy
Cary, NC
Specialty
Urology

Data Provided by:
Bertram Austin Lewis Jr, MD
105 SW Cary Pkwy
Cary, NC
Specialties
Urology
Gender
Male
Education
Medical School: Johns Hopkins Univ Sch Of Med, Baltimore Md 21205
Graduation Year: 1997

Data Provided by:
Dr.Henry A. Unger
(919) 467-3203
105 SW Cary Pkwy # 300
Cary, NC
Gender
M
Education
Medical School: Vanderbilt Univ Sch Of Med
Year of Graduation: 1972
Speciality
Urologist
General Information
Accepting New Patients: Yes
RateMD Rating
2.5, out of 5 based on 1, reviews.

Data Provided by:
Kevin P Perry
(919) 467-3203
105 Sw Cary Pkwy
Cary, NC
Specialty
Urology

Data Provided by:
Data Provided by:

Chemo Regimen for Ovarian Cancer

Provided By:

SUNDAY, Sept. 20 (HealthDay News) -- Dose-dense chemotherapy improves survival in women with advanced ovarian cancer, Japanese researchers say.

Currently, paclitaxel and carboplatin given every three weeks is considered standard first-line chemotherapy for advanced epithelial ovarian cancer. However, dose-dense weekly treatment with paclitaxel is seen as a way to increase progression-free and overall survival in these patients, according to the new study findings.

This phase 3 study of 637 women compared the two approaches. The participants had advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

The 320 patients in the conventional regimen group received six cycles of paclitaxel (180 milligrams per meter squared; three-hour intravenous infusion). The 317 patients in the dose-dense group received paclitaxel (80 milligrams per meter squared; one-hour intravenous infusion) on days one, eight and 15. Both groups received carboplatin on day one of a 21-day cycle.

The patients in the dose-dense group had longer median progression-free survival than those in the standard treatment group (28 months versus 17 months), and longer overall survival at three years (72 percent versus 65 percent). This means that women in the dose-dense group had a 29 percent lower risk of cancer progression and a 25 percent lower risk of death, the authors explained.

Toxicity forced 113 patients in the dose-dense group and 69 patients in the conventional therapy group to stop treatment, the researchers noted. Severe anemia occurred in 214 patients (69 percent) in the dose-dense group and in 137 (44 percent) of the standard therapy group.

The survival benefits seen in the dose-dense group are rare in patients with advanced ovarian cancer, and this regimen offers a new treatment option for women with advanced epithelial ovarian cancer, concluded Dr. Noriyuki Katsumata, of the National Cancer Center Hospital in Tokyo, and colleagues.

The study, published in an upcoming print issue of The Lancet, was released online Sunday to coincide with the European Cancer Organization meeting held Sept. 20 to 24 in Berlin.

"The use of such dose-dense therapy should be decided on an individual basis together with other options for women with advanced-stage ovarian cancer," Dr. Michael A. Bookman, of the Arizona Cancer Center in Tucson, wrote in an accompanying commentary in The Lancet.

More information

The U.S. National Cancer Institute has more about ovarian cancer.

SOURCE: The Lancet, news release, Sept. 19, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com